BICX
vs
S&P 500
BICX
S&P 500
Over the past 12 months, BICX has underperformed S&P 500, delivering a return of +5% compared to the S&P 500's +14% growth.
Stocks Performance
BICX vs S&P 500
Performance Gap
BICX vs S&P 500
Performance By Year
BICX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BioCorRx Inc
Glance View
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The company is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The company is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.